Phenylpropanolamine

Mouse peritonitis model. Groups of CD-1 female mice n 5 group ; were inoculated intraperitoneally IP ; with a lethal dose of S. aureus MSSA or MRSA, 2 x 107 to 5 x 108 CFU mouse ; . The number of mice surviving each day after dosing was recorded for 7 days following inoculation. For trials using immunocompromised mice, 150 mg of cyclophosphamide per kg of body weight was. Consumers can find a free online brochure and learn more about severe allergic emergencies and the Be S.A.F.E. campaign by visiting In October 2006 LifeBack Carriers donated over the patient education section at 25 oxygen carriers to Apria, Lincare, and RoTech, acaai or calling toll free 800 ; 842home medical equipment suppliers. It is our hope 7777. that these carriers will ease some of the burden that parents of premies and infants with respiratory needs face. In November LifeBack CarriersTM will Healthcare professionals can download be donating horseback riding oxygen the quick reference card and find packs to some therapeutic information about the Be S.A.F.E. riding facilities across campaign by visiting the health the nation. LifeBack professionals section of acaai CarriersTM is dedicated . Physicians also can download the Be to improving the lives S.A.F.E. consumer education brochure of respiratory patients by visiting the patient education section no matter their age. of the ACAAI Web site, and can obtain ordering information from the member or health professionals sections. The Be S.A.F.E. campaign is supported by an educational grant from Dey, L.P. About the American College of Allergy, Asthma and Immunology. Above right: The horses wore pink ribbons as the Grey Mares gathered to begin their ride in mid-October. Right: from L to R ; Kerry, Linda, and Lee Golden's solidarity demonstrates that fighting breast cancer is a family affair. Right: Two ladies walk in memory of their sister who passed away from breast cancer.

The study was approved by the South Metropolitan Health Service Human Research Ethics Committee, Western Australia and all subjects provided informed consent. Twenty of the 25. The use of alpha-1 agonist decongestants such as pseudoephedrine and phenylpropanolamine is banned by the international olympic committee ioc ; during competition because of possible ergogenic properties.

In 2005, the American Society of Health-System Pharmacists reported that one 90-bed rural hospital in Kentucky was saving more than 0, 000 a year with the 340B program, while the savings for a 180-bed Michigan hospital topped 0, 000.8 Precise estimates of the actual savings on prescription drugs among 340B program participants are often difficult to measure and compare since prices vary across organizations. Thus, the prices used--whether average manufacturer price, wholesaler discount, 340B ceiling prices or some other metric--might affect the level of savings calculated. For the purposes of this study, an appropriate measure of savings is the difference between the price paid by participants and the price participants would have paid in the absence of the 340B program discount. Survey participants were asked to report their savings, either as actual dollars or a percentage of the hospital pharmacy budget. Respondents from seventy-one hospitals reported their pharmacy savings as dollar amounts. The median monthly savings on total outpatient drugs for these hospitals is approximately , 000 meaning half of the hospitals saved more than that and half saved less ; and the mean savings is reported as , 700 Table 9 ; .iii There is a very wide range, with reporting savings of about 0 per month in one hospital and approximately 8, 000 per month in another. Nineteen respondents reported their savings as a percentage of the pharmacy budget. These hospitals saved an average of 24 percent of the pharmacy budget Table 10 ; . About 96 percent of all respondents stated that they were satisfied with the discount they received. Table 9. Pharmacy savings per month, dollar amount N 71 ; Mean 25th Percentile 50th Percentile Median ; 75th Percentile Dollar $ 19, 688 $ 3, 500 $ 10, 000 $ 27, 083 and photofrin.

Monograph, but the publication auditors would need to be convinced it is not a textbook!" In any case, those peers do matter. As Phillipa McGuinness points out in the case of Mackie: "Vera's not writing that book for Andrew Bolt and his mum. No one expected it was going to be sold in Target. But in her field, Vera is a success story, a scholar of international standing. Bolt's attacks on her have been despicable." Furthermore, the last five years have seen some relief of the siege mentality in the humanities thanks, ironically, to Brendan Nelson, minister since November 2001. He devoted several speeches to promoting their centrality in cultural life; belatedly secured them a Science Engineering and Innovation Council seat, occupied by Iain McCalman; and obtained funding for an advocacy body, the Council for the Humanities, Arts and Social Sciences. Its president, Professor Malcolm Gillies, is one of Australia's most extraordinary scholars, who applied his expertise in patterns of rhetoric in Roman oratory to patterns in pitch notation in the music of Bla Bartk, and who has edited Oxford University Press's Studies in Musical Genesis, Structure The Monthly, May 2006 Gideon Haigh, The Nelson Touch. Indicate that other trace elements are also lower in the overweight group. We conclude that overweight CAPD patients have to be carefully evaluated with respect to undernutrition just as normal-weight patients do. Adequacy of CAPD, measured using Kt V, was lower in the overweight group. Our patients typically perform standard CAPD using 8 L of dialysis solution daily. They are not usually willing to accept a and pilocarpine. 33-46; discussion 50 may 2000 ; issn: 0090-4295 united states pmid 10767450 publication type: journal article, review ; chemical references benzhydryl compounds benzofurans cresols mandelic acids muscarinic antagonists pyrrolidines tolterodine darifenacin phenylpropanolamine oxybutynin topics benzhydryl compounds therapeutic use ; benzofurans therapeutic use ; clinical trials as topic cresols therapeutic use ; humans mandelic acids therapeutic use ; muscarinic antagonists therapeutic use ; phenylpropanolamine pyrrolidines therapeutic use ; urinary bladder diseases complications, drug therapy ; urinary incontinence complications, drug therapy ; curehunter inc provides medical information and specifically does not provide medical advice. Producers, manufacturers and processors of organic foods have to be registered with one of the UK Government-approved organic certification bodies. They are required to keep detailed records ensuring traceability of products from farm, through any processing, to the point of sale. Any major infringement results in suspension of licence and withdrawal of products from the market. All organic farmers, food manufacturers and processors are routinely inspected, as well as being subject to random inspections. The Soil Association's standards are set at a higher level than those laid down by the EU. They are decided by the Soil Association's elected council based on advice from nine widely representative standards committees The Soil Association aims to develop organic standards in line with consumer expectations, which is the Government's policy, as set out in the Organic Action Plan and pima. The authors present data evaluating the pharmacokinetic and pharmacodynamic responses to coadministration of oral linezolid with sympathomimetics pseudoephedrine and phenylpropanolamine ; and a serotonin reuptake inhibitor dextromethorphan. LEVBID, LEVOTHROID, levonorgestrel ethinyl estradiol, levothyroxine sodium, LEVSIN, LEVSIN S L, L-hyoscyamine, LIBRAX, LIDEX * , LIDEX-E * , lidocaine HCl solution & viscous, lindane, LIORESAL * , LIPITOR, lisinopril, lisinopril HCTZ, lithium carbonate, LITHOBID, LO OVRAL * , LOESTRIN, LOESTRIN FE, LOMOTIL * , LOPID * , LOPRESSOR * , LOPROX, lorazepam, LORCET PLUS * , LORTAB * , LOTEMAX, LOTREL, LOZOL * , LUPRON * , LUPRON DEPOT, LYSODREN M MACROBID, MACRODANTIN * , MATULANE, MAXITROL * , MAXZIDE * , mebendazole, meclizine HCl, meclomen, Medrol * , medroxyprogesterone acetate, MEGACE SYRUP, MEGACE * , megestrol acetate, meperidine HCl, MEPHYTON, MEPRON, MESNEX, MESTINON, MESTINON TIMESPAN, methazolamide, metformin HCl, METHERGINE, methocarbamol, methotrexate, methyldopa, methylphenidate HCl, methylphenidate HCl SR, methylprednisolone, metoclopramide, metoprolol, METROCREAM, METRODIN, METROGEL, METROGEL VAGINAL, METROLOTION, metronidazole, mexiletine HCl, MEXITIL * , MIACALCIN NASAL SPRAY, MICRONASE * , MICRONOR, MIDRIN, MINIPRESS * , MINOCIN * , minocycline HCl, MINTEZOL, MIRAPEX, MODICON, MODURETIC * , MONOKET * , MONOPRIL, MONOPRIL HCTZ, morphine sulfate, MOTRIN * , MS CONTIN * , MSIR CAPS, MUCOMYST * , MYAMBUTOL * , MYCELEX TROCHE, MYCOBUTIN, MYCOLOG II * , MYCOSTATIN * , MYLERAN, MYSOLINE * N nadolol, NALDECON PED., NALFON * , NAPROSYN * , naproxen, naproxen sodium, NARDIL, NASACORT, NASACORT AQ, NATACYN, NAVANE * , neomycin sulfate, neomycin polymyxin B, neomycin polymyxin B gramicidin, NEORAL * , NEOSPORIN OPHTH * , NEPTAZANE * , NEUPOGEN, NEURONTIN, NOVOLOG, nifedipine, nifedipine ER, NIFEREX-PN, NILANDRON, NIMOTOP, NITRO-DUR * , nitrofurantoin, nitroglycerin SR caps, nitroglycerin transdermal, NITROSTAT, NIZORAL TABS * , NIZORAL TOPICAL, NOCTEC, NOLVADEX , NORDETTE * , NORPACE * , NORPACE CR * , NORPRAMIN * , nortriptyline HCl, NORVASC, NORVIR, NOVOLIN, nystatin, nystatin-triamcinolone acetonide O OCUFLOX, OGEN * , ORNADE * , ORTHOCEPT, ORTHO-CYCLEN, ORTHO-NOVUM ALL COMBINATIONS ; , ORTHO TRI-CYCLEN, ORTHO TRI-CYLCEN LO, ORUDIS * , ORUVAIL * , OVRAL * , oxazepam, oxybutynin Cl, oxycodone APAP, oxycodone ASA, OXYCONTIN, OXYIR * P PAMELOR * , pancrelipase, PARLODEL * , PAXIL, PAXIL CR, PEDIAZOLE * , pemoline, penicillin VK, PENTASA, pentazocine HCl naloxone HCl, pentoxifylline, PERCOCET * , PERCODAN * , PERMAX, permethrin, perphenazine, perphenazine amitriptyline HCl, PERSANTINE * , phenazopyridine HCl, PHENERGAN, PHENERGAN VC W CODEINE * , PHENERGAN W CODEINE * , phenobarbital, phenylpropanolamine guaifenesin, PILOCAR, PILOPINE HS, piroxicam, PLAQUENIL * , podofilox, polyethylene glycol electrolyte soln, polymixin B sulf trimethoprim, polymixin B sulf bacitracin zn, POLYSPORIN OPHTH * , POLYTRIM OPHTH * , polyvitamins w fluoride, polyvitamins w fluoride & iron, POLY-VI-FLOR * , POLY-VI-FLOR WITH IRON * , potassium supplements, prazosin, PRED FORTE * , PRED-G, prednisolone acetate, prednisolone sod phos sulfacetamide, prednisone, PRELONE * , PREMARIN, PREMARIN VAGINAL CREAM, PREMPHASE, PREMPRO, PREVACID, PREVPAC, primidone, probenecid, procainamide HCl, procainamide HCl SR, PROCAN * , PROCAN SR * , PROCARDIA * , PROCARDIA XL * , PROCARDIA XL 90MG, prochlorperazine, PROCRIT, PROCTOFOAM-HC, PROFASI * , PROGRAF, PROLOPRIM * , promethazine, propafenone, PROPINE * , propoxyphene napsylate APAP, propranolol HCl, propranolol HCl HCTZ, PROVENTIL HFA, PROVENTIL * , PROVERA * , PROZAC * , pseudoephedrine guaifenesin, PSORCON * , PTU, PULMOZYME, PURINETHOL, pyrazinamide, PYRIDIUM * Q QUESTRAN * , QUINAGLUTE * , quinidine gluconate ER R REGLAN * , RELENZA, REQUIP, RESCRIPTOR, reserpine, RESTORIL * , RETIN-A * , RETIN-A MICRO, RETROVIR, RIDAURA, RIMACTANE * , RISPERDAL, RITALIN SR * , ROBAXIN * , ROBITUSSIN AC * , ROBITUSSIN DAC * , ROCALTROL, RONDEC, RONDEC DM, ROWASA, r-tannate, r-tannate pediatric, RYTHMOL * S SANDIMMUNE, selegiline HCl, SEPTRA DS * , SERAX * , SEREVENT, SERZONE, SINGULAIR 4mg , SILVADENE * , silver sulfadiazine, SINEMET * , SINEMET CR * , SINEQUAN * , SLO-BID, smx tmp, sodium fluoride tabs & drops, sodium polystyrene sulfonate, SOMA * , SORIATANE, sotalol HCl, SPECTAZOLE, spironolactone, spironolactone HCTZ, STARLIX, sucralfate, SULAR, sulfacetamide sod., sulfasalazine, sulfathiazole sulfacetamide sulfabenzamide, sulfisoxazole, sulindac, SUPRAX, SUSTIVA, SYMMETREL * , SYNALAR * , SYNAREL SPRAY, SYNTHROID T TAGAMET * , TALWIN NX * , TAMBOCOR, TAPAZOLE, TARGRETIN, TAVIST * , TEGRETOL, TEGRETOL XR, temazepam, TEMODAR, TENORETIC * , TENORMIN * , TEQUIN, terazosin, TESLAC, TESSALON PERLES * , tetracycline HCl, THEO-24, THEO-DUR, theophylline E.R., thioguanine, thioridazine HCl, thiothixene, THORAZINE, TICLID * , ticlopidine HCl, TILADE, timolol, TIMOPTIC * , TIMOPTIC XE * , TOBRADEX, tobramycin ophth. soln, TOBREX OPHTH. OINT, TOFRANIL * , tolmetin sodium, TONOCARD, TOPAMAX, TOTACILLIN * , tramadol HCl, triple vitamins w fluoride, triple vitamins w fluoride & iron, TRANSDERM SCOP, trazodone HCl, TRENTAL * , triamcinolone acetonide dental paste, triamcinolone acetonide, triamterene HCTZ, TRIAVIL * , triazolam, trihexyphenidyl HCl, TRILAFON * , TRILISATE * , trimethoprim, TRI-NORINYL, TRIPHASIL * , TRIPLE SULFA * , TRI-VI-FLOR * , TRI-VI-FLOR WITH IRON * , TRIZIVIR, tropicamide U UAA, ULTRAM * , ULTRAVATE, UNIPHYL, URECHOLINE * , UROCIT-K, URSO V VALISONE * , VALIUM * , valproic acid, VANCOCIN, VANTIN, VASOCIDIN * , VELOSULIN, VENTOLIN * , VENTOLIN ROTOCAPS, VEPESID, verapamil HCl, verapamil HCl SR, VERMOX * , VESANOID, VIBRAMYCIN * , VICODIN * , VICODIN-ES * , VIDEX, VIOKASE, VIRA-A, VIRACEPT, VIRAMUNE, VIROPTIC, vitamin A, VOLMAX, VOLTAREN * , VOSOL * W W ELLBUTRIN * , W ELLBUTRIN SR, W ELLCOVORIN * , W ESTCORT * , W IGRAINE and pindolol.
On the basis of the response, both rapporteurs draft a joint response to the questions and provide it to the CHMP and EMEA, which then may comment on it. The applicant also receives a copy for information purposes. At that point, the CHMP may decide to request oral explanations from the applicant, who can also ask for the oral hearing on his own. If there is a hearing, the clock stops again. Then, the final draft of the SMPC, package leaflet, etc. are provided and on the 210th day at the latest, the CHMP opinion together with the assessment report are issued. The CHMP tries to decide on the basis of scientific consensus, but if no consensus can be reached, a majority vote will prevail and the diverging opinions have to be reflected in the assessment report. In case of an unfavorable opinion, the applicant has to be informed immediately and provided with the CHMP assessment report, which states the reasons for a negative opinion and dissenting votes of members of the CHMP if any. The same applies when the CHMP requires the SmPC to be changed, considers that the labeling or package leaflet is not in accordance with the legal requirements, or that the authorization can only be granted subject to conditions. In these cases, the applicant may request in writing within 15 days after the receipt of the opinion ; that the opinion be reassessed. The request has to be supported by a written explanation within 60 days after the receipt of the opinion. The CHMP then has to reassess its opinion within 60 days after the receipt of the written explanation through newly appointed rapporteurs. However, the review is restricted to the questions raised by the applicant in its appeal and may only be based on scientific information that had already been provided to the CHMP when issuing its first opinion. The applicant may also request to involve a scientific advisory committee at that point. The CHMP must draft a final opinion, which includes the conclusions of the reassessment. Phenylpropanolamine PPA ; This mild stimulant, available in such preparations as Phenoxine and Dexatrim is sold over-the-counter as timed release or slow-acting preparations. PPA is also available by prescription in more concentrated form. PPA can be a valuable anorexient because of its rapid action. One can take the fast-release versions about half an hour before anticipating temptation and they will be finished working in a few hours. In all likelihood, PPA, like amphetamine-related compounds, stimulates accumulation of norepinephrine and dopamine in synapses. It has some similar side effects, which include insomnia, blood sugar and blood pressure elevation, rapid heart rate, sweating and agitation. When used in combination with another anorexient, Ltyrosine an amino acid ; , the effectiveness of both are sometimes enhanced and pitocin. The sample is ground to 100200 mesh 150 75 m ; . Wet samples are mixed with either ASE Prep DE diatomaceous earth ; , P N 062819 1: w w ; , air dried.1 After grinding, a weighed sample is transferred to either a 11- or 22-mL extraction cell.
Loss. Phenylpropanolamine is the only noradrenergic drug that is available for weight control over-the-counter Table 2 ; . It also sold in many nasal decongestants. In a review of this drug, an advisory panel to the Food and Drug Administration concluded that it was probably safe and effective. At high doses 75 mg ; it has been reported to increase blood pressure. A critical review of published and unpublished studies with this drug supports this contention 6 ; . In one group offive clinical trials with phenylpropanolamine alone, the drug-treated individuals lost an average of 0.24 kg wk more than the placebo-treated group. This and posture. Table 1 Dermatophyte identification of 31 clinical samples studied Samples T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. rubrum T. tonsurans T. tonsurans T. tonsurans T. tonsurans T. tonsurans T. tonsurans T. mentagrophytes T. mentagrophytes T. mentagrophytes T. mentagrophytes M. canis M. gypseum Reference number 11 16 22 Location Inguinal region Foot Foot Foot Foot Foot Foot Foot Nail Nail Nail Foot Foot Foot Glutea region Nail Nail Nail Nail Scalp Nail Foot Foot Nail Nail Foot Nail Nail Foot Nail Foot.
Fda health advisory phenylpropanolamine ppa ; site the food and drug administration fda ; is taking steps to remove phenylpropanolamine ppa ; from all drug products and has requested that all drug companies discontinue marketing products containing ppa and pram.

E. Clinical Trials Plaintiffs' experts also rely on human clinical trials. E.g., Paul R. Pentel Toxicity of Overthe-Counter Stimulants, 252 JAMA 1898 1984 J.D. Horowitz et al., Hypertensive Reponses Induced by Phenylpropanolamine in Anorectic and Decongestant Preparations, 8159 The Lancet 60, 61 1980 Steven C. Dilsaver et al., Complications of Phenylpropanolamine, 39 4 ; Am. Fam. Physician 201, 201-06 1989 ; . The most common adverse effect of PPA in these clinical trials was a sudden rise in blood pressure. Other clinical trials have examined the potential synergistic effects of PPA and caffeine, specifically studying the combinations ability to cause transient hypertension. C. Raymond Lake et al., Transient Hypertension after Two Phenylpropanolamine Diet Aids and the Effects of Caffeine: A Placebo-Controlled Follow-Up Study, 86 Am. J. Med. 427, 427-32 1989 ; . The plaintiffs' experts contend that transient blood pressure spikes can cause hemorrhagic stroke while conceding that the precise mechanism of action is unknown. f. Retrospective Stroke Study The plaintiffs' experts also rely upon a retrospective analysis of more than 1, 700 stroke patients who were admitted to the National Institute of Neurology and Neurosurgery in Mexico City, Mexico from 1986 until 1997. Jose Luis Ruiz-Sandoval et al., Intracerebral Hemorrhage In Young People: Analysis of Risk Factors, Location, Causes, and Prognosis, 30 Stroke 537, 541 1999 ; . The study concluded that "the use of phenylpropanolamine was responsible" for seven cases of intercerebral hemorrhagic stroke. Id. g. Rechallenge Data Plaintiffs cannot produce rechallenge data specific to stroke for ethical reasons. However, Dr. Lake noted a rechallenge event involving a 28 year-old female psychiatric patient who ingested more than four times the recommended amount of PPA and less than one day later suffered paranoid psychosis and a grand mal seizure. C. Raymond Lake et al., Adverse Drug Effects Attributed to Phenylpropanolamine: A Review of 142 Case Reports, 89 Am. J. Med. 195, 205 1990 ; . Rechallenge with PPA caused recurrence of some of her symptoms. Dr. Lake closed his article by writing, "Although conclusive statements about the danger or safety of PPA are still premature, caution appears prudent conscientious attention to PPA ADRs will heighten physician awareness and will serve to resolve this controversial issue." Id. at 206. 3. Differential Diagnosis Is Routinely Performed by Experts in The Field.
No warnings about adverse effects of drugs n 48 ; . Neither intervention n 34 and pramlintide.

A 42 year old female developed syncope and breathlessness post partum and was found to have idiopathic PAH. Initial treatment with an ERA failed but she responded modestly to a prostacyclin analogue which eventually failed. Atrial septostomy for recurrent syncope was refused. Double lung transplantation was successful. Contribution plans for 2000, 1999 and 1998 totaled , 902, 000, , 587, 000 and , 715, 000, respectively. OTHER POSTRETIREMENT BENEFITS: The Company provides postretirement health care and life insurance benefits for retired employees of most domestic locations and Canada. Most full-time employees become eligible for these benefits after attaining specified age and service requirements. Although the Company sold the Cyanamid Agricultural Products business see Note 2 ; , which was accounted for as a discontinued operation, the pensions and other postretirement benefits were excluded from the sale for U.S. plans since employees of the Cyanamid Agricultural Products business accrued benefits in plans that encompassed other business segments. Except for one pension plan in Germany, all international plans will continue to be maintained by the Company to pay benefits that were accrued prior to the sale. Accordingly, benefit obligations, fair value of plan assets and accrued benefit liabilities were not restated, except to reflect the sale of the pension plan in Germany. However, components of net periodic benefit cost from continuing operations were restated to reflect the Cyanamid Agricultural Products business as a discontinued operation. The change in benefit obligation, change in plan assets and reconciliation of funded status of the Company's defined benefit plans principally U.S. plans ; for 2000 and 1999 were as follows and praziquantel and phenylpropanolamine.

Forget about it and go on." I calmed down about the camera, which actually belongs to my school, and Pat delivered it safe and sound back at the hotel. Later, Les and I compared the 12 Step Program to Hindu philosophy. In meditation, you only meditate on the good, on the positive, on peace which is the opposite of anger ; . You meditate on the pattern of thoughts from which action is based. Out of a variety of thoughts, you focus on one. You think only of good. You are what you think. In the 12 step program, you focus on your feelings about an event, not the event itself, which cannot be changed. You think, "I energy using this body for expression." Meditation is a connection to the external energy source which is God. We had dinner at the Anna University Club. The Vice Chancellor of the University was supposed to come, but never showed, although his wife did. The Head of the Department was very nervous. They appeared not to get along well. The next morning, we visited a public Montessori school, which is actually privately funded. All the students wore uniforms, and all the girls had their hair in two braids. Students walk in single file. One girl dropped her bicycle on the way to the bike rack. Immediately, two girls came to her aid. At the entrance to the school, a student wrote first in English, then in Tamil: "The body is purified by water. The mind is purified by truthfulness." Indian society is truly permeated by philosophy and character building is taught unabashedly in the schools. Morality is actually taught for one period each day. The children were all wellbehaved and excited to see us and perform their dances.
Riddell and Khalili supply from branches of the inferior phrenic artery, the aorta, and the renal artery, forming a plexus around the outer zona glomerulosa. There is however a single draining vein and therefore an abrupt change in flow dynamics in the medullary sinusoids draining into the adrenal vein. This change may predispose the gland to microvascular thrombosis in situations of procoagulable states and during episodes of hypotension, leading to infarction. It is at the time of reperfusion through these necrotic vessels that hemorrhage is thought to occur, especially in situations of prolonged anticoagulation therapy [6]. Heparin-induced thrombocytopenia is also a recognized cause of bilateral adrenal swelling due to hemorrhage. The cause of the hemorrhage is again thought to be secondary to microvascular thrombosis and subsequent ischemic damage to the vascular endothelium [6]. The lack of hemorrhage on MRI performed in our patient indicates that although the patient was thought to have heparin-induced thrombocytopenia, it is unlikely to have been the cause for the sequential adrenal enlargement. The abdominal pain has mainly been ascribed to hemorrhage within the gland, but a recent article [7] disputes this cause, suggesting that it is more likely to be due to ischemic necrosis and associated inflammatory swelling. The findings in our patient would support the latter view. In our extensive literature review, we found five cases in which the adrenal glands on CT scans were swollen but of normal density on an unenhanced study. This finding would suggest infarction with no associated hemorrhage. In one of these cases, it was postulated that there could have been hemorrhage that was of normal density on CT [8]; on the basis of the experience with our patient, we believe this finding is unlikely. In none of these other cases was MRI performed after CT. MRI provides a highly sensitive method of detecting hemorrhage, and as we have shown, offers exquisite detail of the adrenal glands. Gradient-echo T1-weighted images show hyperintense areas corresponding to methemoglobin and hypointense regions in the more chronic stage due to hemosiderin. T2-weighted images show edematous change related to the inflammatory swelling of the adrenal gland. The fact that relatively few cases of pure adrenal infarction have been reported is likely, to some degree, to reflect the fact that MRI is not often performed in such cases. The absence of blood products is not fully appreciated on CT. The importance of showing the presence or absence of macroscopic adrenal hemorrhage is related to future treatment of the underlying condition of these patients. A risk of recurrent hemorrhage always exists if anticoagulation therapy is restarted, although the risk of thrombosis in a patient with untreated antiphospholipid-antibody syndrome has to be weighed against the potential for recurrent adrenal hemorrhage. After macroscopic hemorrhage, the anticoagulant regime may well be altered or stopped entirely, depending on the clinical history. If pure infarction is shown, as with our patient, anticoagulation therapy does not offer such a potential increased risk, and the regime is unlikely to be changed. We conclude that adrenal infarction is a rare complication of antiphospholipid-antibody syndrome but should be considered in the differential diagnosis for causes of acute abdominal pain in patients with underlying hypercoagulable conditions. MRI may be used to assess underlying hemorrhage in the adrenal glands if this is not apparent on the initial CT and prevnar.
In november 2000, the food and drug administration fda ; issued a public health warning for phenylpropanolamine and requested that all drug companies discontinue marketing products containing phenylpropanolamine due to the drug's association with risk for hemorrhagic stroke. It is interesting to note that EthA and EthR orthologs are also present in M. avium and M. leprae. The EthAR loci of M. avium and M. tuberculosis share a very similar architecture. In both cases, the two genes are oriented "head to head" and are separated by a putative 76-bp divergent promoter. In contrast, the two M. leprae orthologs are not located in the same locus. The initiation codons of the M. leprae EthA and EthR are found in the genome in positions 86, 698 and 1, 235, 214, respectively. The genome of M. leprae seems to be reduced to a minimal pool of genes essential to the survival of this strictly intracellular pathogen. In contrast to many genes of M. leprae, EthA and EthR are apparently not truncated and are highly similar to their orthologs in M. tuberculosis and M. smegmatis. Altogether, these observations suggest that these genes have an important role in vivo. In addition, the M. tuberculosis genome possibly encodes more than 30 monooxygenases, and the relative role of each enzyme in the oxidation of ETH remains to be assessed in vivo. The understanding of the mode of action of ETH is valuable for the design of improved versions of the drug, for the elaboration of potentiating agents, and for the understanding of drug resistance. Finally, an intriguing question, which awaits further experimentation, concerns the possibility of an equivalent mechanism of regulation of katG and INH resistance. 39% compared with 20% ; , family history of hemorrhagic stroke 9% compared with 5% ; , heavy alcohol use 14% compared with 7% ; , and recent cocaine use 2% compared with 1% ; . For all other clinical variables examined, case and control subjects were not dissimilar. Table 3 shows non-PPA pharmacological exposures of case and control subjects. Case subjects were significantly p 0.05 ; less likely to report use of NSAIDS and significantly more likely to report use of caffeine and nicotine in the three days before their focal time. To identify variables for inclusion in subsequent multivariable models, we sequentially tested each clinical feature Table 2 ; and pharmacological exposure Table 3 ; in the basic conditional logistic model that included race, hypertension, and current cigarette smoking. Under any PPA exposure definition, only education changed the adjusted odds ratio for the association between PPA and hemorrhagic stroke by more than 10% and was included in all subsequent models. Association Between PPA and Hemorrhagic Stroke Our first co-equal specified aim was to determine whether PPA users, compared to non-users have an increased risk of hemorrhagic stroke. In Table 4, frequencies are shown for exposures to PPA in an unmatched format for the case and control subjects, with unadjusted and adjusted matched odds ratios provided. See Appendix C for exposures presented in matched format. ; The odds ratios were calculated from conditional logistic models for matched sets; the adjusted models included the same four variables: race, history of hypertension, current cigarette smoking, and education. For any use of PPA within three days either for cough-cold remedy or appetite suppression ; , the unadjusted odds ratio was 1.67 p 0.040 ; and the adjusted odds ratio was 1.49 lower limit of the one-sided 95% confidence interval LCL ; 0.93, p 0.084 ; . Our second co-equal specific aim was to estimate the association between use of PPA and hemorrhagic stroke according to type of PPA exposure. The results are shown in Table 4. See Appendix C for exposures presented in matched format. ; For the association between PPA use in cough-cold remedies within the three-day exposure window, the unadjusted odds ratio was 1.38 p 0.163 ; . The adjusted odds ratio was 1.23 LCL 0.75, p 0.245 ; . For the association between PPA use in appetite suppressants within the three-day exposure window, the unadjusted odds ratio was 11.98 p 0.007 ; and the adjusted odds ratio was 15.92 LCL 2.04, p 0.013 ; . To examine the relation between recency of PPA exposure and risk for hemorrhagic stroke, we calculated odds ratios according to the timing of most recent PPA use Table 5 ; . For this analysis, the pre-specified definition for current use was use of any PPA-containing product on the index day before focal time or the preceding calendar day. Prior use was defined as use two or three calendar days before the focal time. As shown in the table, the odds ratio was slightly higher for current use adjusted OR AOR ; 1.61, LCL 0.93, p 0.078 ; than for prior use AOR 1.16, LCL 0.47, p 0.393 ; . Within current use, we then calculated odds ratios according to first use or not-first use. First use was defined as current use with no other use within the prior two weeks. Not-first use included other uses within the two-week interval. The odds ratio was higher for first use AOR 3.14, LCL 1.16, p 0.029 ; than for not-first use AOR 1.20, LCL 0.61, p 0.329 ; . All first uses of PPA n 13 ; reported in these data were in cough-cold remedies. Our final co-equal specific aim was to estimate the association between PPA and risk for hemorrhagic stroke among women for two exposure definitions: appetite suppressant use within three days and first dose use See Appendix D ; . For the association between PPA in appetite suppressants and risk for hemorrhagic stroke among women, the unadjusted odds ratio was 12.19 p 0.006 ; and the adjusted odds ratio was 16.58 LCL 2.22, p 0.011 ; . Among HSP subjects, all appetite suppressant use within the three-day exposure window occurred among women. For first dose PPA uses, eleven of the 13 exposures were among women seven cases compared with four controls ; . The unadjusted odds ratio was 3.50 p 0.039 ; and the adjusted odds ratio was 3.13 LCL 1.05, p 0.042 ; . Appendix C shows exposure data for cases and controls in a matched format. Additional Analyses Based on the findings that risk for hemorrhagic stroke seemed to be concentrated among current users, we examined the association between current PPA dose and risk for hemorrhagic stroke. Among 21 exposed control subjects, the median current dose of PPA i.e., total amount taken on the index day or preceding day ; was 75mg. Analysis according to dose shows that the odds ratio was higher for current doses above the median 75mg ; AOR 2.31, LCL 1.10, p 0.031 ; than for lower doses AOR 1.01, LCL 0.43, p 0.490 ; . Among first dose users, four of eight cases and two of five controls were exposed to 75mg of PPA. To examine the potential effect of ambiguity in the correct focal time, we recalculated the odds ratios after excluding all 154 case subjects who were classified as having a definite n 76 ; or uncertain n 78 ; sentinel symptom. The magnitude of the adjusted odds ratios did not change substantially see Appendix E ; . We also recalculated the odds ratios using the alternate focal time data for the 53 patients who, with their Phenylpropanolamine and Risk of Hemorrhagic Stroke 6.